UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 307

Sortiert nach

Phase II Clinical Trial of a Granulocyte-Macrophage Colony-Stimulating Factor–Encoding, Second-Generation Oncolytic Herpesvirus in Patients With Unresectable Metastatic Melanoma

Journal of clinical oncology, 2009-12, Vol.27 (34), p.5763-5771

2009

Link zum Volltext

Verfügbarkeit prüfen

First-in-Human, Multicenter, Phase I Dose-Escalation and Expansion Study of Anti-Mesothelin Antibody-Drug Conjugate Anetumab Ravtansine in Advanced or Metastatic Solid Tumors

Journal of clinical oncology, 2020-06, Vol.38 (16), p.1824-1835

2020

Link zum Volltext

Verfügbarkeit prüfen

Placebo-Controlled Phase III Trial of Immunologic Therapy with Sipuleucel-T (APC8015) in Patients with Metastatic, Asymptomatic Hormone Refractory Prostate Cancer

Journal of clinical oncology, 2006-07, Vol.24 (19), p.3089-3094

2006

Link zum Volltext

Verfügbarkeit prüfen

A first in human phase 1 study of CG0070, a GM-CSF expressing oncolytic adenovirus, for the treatment of nonmuscle invasive bladder cancer

The Journal of urology, 2012-12, Vol.188 (6), p.2391

2012

Link zum Volltext

Verfügbarkeit prüfen

Randomized Phase II Trial Comparing Bevacizumab Plus Carboplatin and Paclitaxel With Carboplatin and Paclitaxel Alone in Previously Untreated Locally Advanced or Metastatic Non-Small-Cell Lung Cancer

Journal of clinical oncology, 2004-06, Vol.22 (11), p.2184-2191

2004

Link zum Volltext

Verfügbarkeit prüfen

Avelumab in patients with previously treated metastatic melanoma: phase 1b results from the JAVELIN Solid Tumor trial

Journal for immunotherapy of cancer, 2019-01, Vol.7 (1), p.12-12, Article 12

2019

Link zum Volltext

Verfügbarkeit prüfen

Analysis of Adenoviral p53 Gene Therapy Clinical Trials in Recurrent Head and Neck Squamous Cell Carcinoma

Frontiers in oncology, 2021-04, Vol.11, p.645745-645745

2021

Link zum Volltext

Verfügbarkeit prüfen

Induction of Immune Responses and Clinical Efficacy in a Phase II Trial of IDM-2101, a 10-Epitope Cytotoxic T-Lymphocyte Vaccine, in Metastatic Non–Small-Cell Lung Cancer

Journal of clinical oncology, 2008-09, Vol.26 (27), p.4418-4425

2008

Link zum Volltext

Verfügbarkeit prüfen

First-in-man application of a novel therapeutic cancer vaccine formulation with the capacity to induce multi-functional T cell responses in ovarian, breast and prostate cancer patients

Journal of translational medicine, 2012-08, Vol.10 (1), p.156-156, Article 156

2012

Link zum Volltext

Verfügbarkeit prüfen

Resident Memory T Cells and Their Effect on Cancer

Vaccines (Basel), 2020-10, Vol.8 (4), p.562

2020

Link zum Volltext

Verfügbarkeit prüfen

Exploring the safety, effect on the tumor microenvironment, and efficacy of itacitinib in combination with epacadostat or parsaclisib in advanced solid tumors: a phase I study

Journal for immunotherapy of cancer, 2022-03, Vol.10 (3), p.e004223

2022

Link zum Volltext

Verfügbarkeit prüfen

Subclonal landscape of cancer drives resistance to immune therapy

Cancer treatment and research communications, 2022-01, Vol.30, p.100507-100507, Article 100507

2022

Link zum Volltext

Verfügbarkeit prüfen

Randomized, Double-Blind, Phase II Study of Ruxolitinib or Placebo in Combination With Capecitabine in Patients With Metastatic Pancreatic Cancer for Whom Therapy With Gemcitabine Has Failed

Journal of clinical oncology, 2015-12, Vol.33 (34), p.4039-4047

2015

Link zum Volltext

Verfügbarkeit prüfen

Are vaccines making a comeback in non-small-cell lung cancer?

Journal of clinical oncology, 2008-03, Vol.26 (9), p.1402-1403

Nemunaitis, John J

2008

Link zum Volltext

Verfügbarkeit prüfen

Safety and Activity of Varlilumab, a Novel and First-in-Class Agonist Anti-CD27 Antibody, in Patients With Advanced Solid Tumors

Journal of clinical oncology, 2017-06, Vol.35 (18), p.2028-2036

2017

Link zum Volltext

Verfügbarkeit prüfen

Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer

Journal for immunotherapy of cancer, 2017-03, Vol.5 (1), p.22-22, Article 22

2017

Link zum Volltext

Verfügbarkeit prüfen

A first-in-human, phase 1, dose-escalation study of dinaciclib, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignancies

Journal of translational medicine, 2013-10, Vol.11 (1), p.259-259

2013

Link zum Volltext

Verfügbarkeit prüfen

Pegylated Interferon Alfa-2b Treatment for Patients With Solid Tumors: A Phase I/II Study

Journal of clinical oncology, 2002-09, Vol.20 (18), p.3841-3849

2002

Link zum Volltext

Verfügbarkeit prüfen

Randomized Phase II Trial Comparing Bevacizumab Plus Carboplatin and Paclitaxel With Carboplatin and Paclitaxel Alone in Previously Untreated Locally Advanced or Metastatic Non-Small-Cell Lung Cancer

Journal of clinical oncology, 2023-05, Vol.41 (13), p.2305-2312

2023

Link zum Volltext

Verfügbarkeit prüfen

Cutaneous head and neck melanoma in OPTiM, a randomized phase 3 trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor for the treatment of unresected stage IIIB/IIIC/IV melanoma

Head & neck, 2016-12, Vol.38 (12), p.1752-1758

2016

Link zum Volltext

Verfügbarkeit prüfen

Survivin-targeted immunotherapy drives robust polyfunctional T cell generation and differentiation in advanced ovarian cancer patients

Oncoimmunology, 2015-08, Vol.4 (8), p.e1026529-e1026529

2015

Link zum Volltext

Verfügbarkeit prüfen

Antitumor activity and safety of combination therapy with the Toll-like receptor 9 agonist IMO-2055, erlotinib, and bevacizumab in advanced or metastatic non-small cell lung cancer patients who have progressed following chemotherapy

Cancer Immunology, Immunotherapy, 2014-08, Vol.63 (8), p.787-796

2014

Link zum Volltext

Verfügbarkeit prüfen

Liposomal insulin promoter–thymidine kinase gene therapy followed by ganciclovir effectively ablates human pancreatic cancer in mice

Cancer letters, 2015-04, Vol.359 (2), p.206-210

2015

Link zum Volltext

Verfügbarkeit prüfen

Phase I study of intravenously administered ATI-1123, a liposomal docetaxel formulation in patients with advanced solid tumors

Cancer chemotherapy and pharmacology, 2014-12, Vol.74 (6), p.1241-1250

2014

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 307

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(295)
Mit Volltextzugriff
(279)

Publikationsform

Artikel
(306)
Berichte
(1)

Sprache

Englisch
(307)
Japanisch
(14)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Phase II Clinical Trial of a Granulocyte-Macrophage Colony-Stimulating Factor–Encoding, Second-Generation Oncolytic Herpesvirus in Patients With Unresectable Metastatic Melanoma

First-in-Human, Multicenter, Phase I Dose-Escalation and Expansion Study of Anti-Mesothelin Antibody-Drug Conjugate Anetumab Ravtansine in Advanced or Metastatic Solid Tumors

Placebo-Controlled Phase III Trial of Immunologic Therapy with Sipuleucel-T (APC8015) in Patients with Metastatic, Asymptomatic Hormone Refractory Prostate Cancer

A first in human phase 1 study of CG0070, a GM-CSF expressing oncolytic adenovirus, for the treatment of nonmuscle invasive bladder cancer

Randomized Phase II Trial Comparing Bevacizumab Plus Carboplatin and Paclitaxel With Carboplatin and Paclitaxel Alone in Previously Untreated Locally Advanced or Metastatic Non-Small-Cell Lung Cancer

Avelumab in patients with previously treated metastatic melanoma: phase 1b results from the JAVELIN Solid Tumor trial

Analysis of Adenoviral p53 Gene Therapy Clinical Trials in Recurrent Head and Neck Squamous Cell Carcinoma

Induction of Immune Responses and Clinical Efficacy in a Phase II Trial of IDM-2101, a 10-Epitope Cytotoxic T-Lymphocyte Vaccine, in Metastatic Non–Small-Cell Lung Cancer

First-in-man application of a novel therapeutic cancer vaccine formulation with the capacity to induce multi-functional T cell responses in ovarian, breast and prostate cancer patients

Resident Memory T Cells and Their Effect on Cancer

Exploring the safety, effect on the tumor microenvironment, and efficacy of itacitinib in combination with epacadostat or parsaclisib in advanced solid tumors: a phase I study

Subclonal landscape of cancer drives resistance to immune therapy

Randomized, Double-Blind, Phase II Study of Ruxolitinib or Placebo in Combination With Capecitabine in Patients With Metastatic Pancreatic Cancer for Whom Therapy With Gemcitabine Has Failed

Are vaccines making a comeback in non-small-cell lung cancer?

Safety and Activity of Varlilumab, a Novel and First-in-Class Agonist Anti-CD27 Antibody, in Patients With Advanced Solid Tumors

Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer

A first-in-human, phase 1, dose-escalation study of dinaciclib, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignancies

Efficacy and Safety of Avelumab Treatment in Patients With Advanced Unresectable Mesothelioma: Phase 1b Results From the JAVELIN Solid Tumor Trial

Pegylated Interferon Alfa-2b Treatment for Patients With Solid Tumors: A Phase I/II Study

Randomized Phase II Trial Comparing Bevacizumab Plus Carboplatin and Paclitaxel With Carboplatin and Paclitaxel Alone in Previously Untreated Locally Advanced or Metastatic Non-Small-Cell Lung Cancer

Cutaneous head and neck melanoma in OPTiM, a randomized phase 3 trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor for the treatment of unresected stage IIIB/IIIC/IV melanoma

Survivin-targeted immunotherapy drives robust polyfunctional T cell generation and differentiation in advanced ovarian cancer patients

Antitumor activity and safety of combination therapy with the Toll-like receptor 9 agonist IMO-2055, erlotinib, and bevacizumab in advanced or metastatic non-small cell lung cancer patients who have progressed following chemotherapy

Liposomal insulin promoter–thymidine kinase gene therapy followed by ganciclovir effectively ablates human pancreatic cancer in mice

Phase I study of intravenously administered ATI-1123, a liposomal docetaxel formulation in patients with advanced solid tumors

Suchergebnisse filtern